Sarepta Therapeutics (SRPT) Cash from Operations (2010 - 2026)

Sarepta Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 202683000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 65.26% year-over-year to 202683000.0; the TTM figure through Mar 2026 stood at 175275000.0 (up 132.03% YoY), while the FY2025 annual figure was 205479000.0, changed 0.15% from the prior year.
• Cash from Operations was 202683000.0 for Q1 2026 at Sarepta Therapeutics, down from 131206000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 261337000.0 in Q2 2025 to a low of 583437000.0 in Q1 2025.
• Historically, Cash from Operations has averaged 84722823.53 across 5 years, with a median of 70699000.0 in 2024.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations plunged 215.05% in 2022, then soared 1649.01% in 2025.
• A 5-year view of Cash from Operations shows it stood at 92392000.0 in 2022, then surged by 40.84% to 54657000.0 in 2023, then jumped by 268.41% to 92046000.0 in 2024, then soared by 42.54% to 131206000.0 in 2025, then sank by 254.48% to 202683000.0 in 2026.
• The last three Cash from Operations figures came in at 202683000.0 (Q1 2026), 131206000.0 (Q4 2025), and 14585000.0 (Q3 2025), per Business Quant data.